I wish i could but unfortunately i can’t. see you in the afterlife
Study all your notes. Notes are always the way to go.
Its true just took the test.
Answer:
I think a Lack of executive management support for the risk assessment. ...
Lack of established ground rules for conducting the risk assessment.
Double-blind design: this is how the study will be conducted. This means that in this study, participants will know which treatments are being applied to each participant. In this case, the researcher can hire a doctor or health professional who can deliver the different treatments to the participants without the researcher and the participants themselves knowing what treatment is being delivered and which participants are not receiving any treatment.
Antagonist: It will be a substance used to establish connections in the participants' neurological receptors, but without activating these receptors and preventing any other substance from activating them.
Acetylcholine: Will be the neurotransmitter tested in treatments, as it is the main neurotransmitter often related to the symptoms of Parkinson's disease, alzheimer's disease, multiple sclerosis and schizophrenia
Positron Emission Tomography (PET): It will allow the visualization of images that will allow the evaluation of the functioning of the neurotransmitters related to each tested treatment.
Blood-brain barrier: It will allow the assessment of the metabolic function of the participants' brain, as it protects the nervous system from toxic and harmful substances. This cerebral metabolic function will be evaluated in relation to each treatment applied.
Myelin sheath: is the protective layer of nerve cells. It is usually damaged in people who have Parkinson's disease, alzheimer's disease, multiple sclerosis and schizophrenia, for this reason, it will allow the assessment of their protection in relation to each treatment tested.
